Business Description
![Regeneron Pharmaceuticals Inc Regeneron Pharmaceuticals Inc logo](https://static.gurufocus.com/logos/0C000008R4.png?14)
Regeneron Pharmaceuticals Inc
NAICS : 325412
SIC : 2834
ISIN : US75886F1075
Share Class Description:
WBO:REGN: Ordinary SharesCompare
Compare
Traded in other countries / regions
REGN.USA0R2M.UKREGN34.BrazilREGN.MexicoRGO.Germany1REGN.ItalyREGN.Austria IPO Date
2017-05-22Description
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including Eylea, approved for wet age-related macular degeneration and other eye diseases; Praluent for LDL cholesterol lowering; Dupixent in immunology; Libtayo in oncology; and Kevzara in rheumatoid arthritis. Regeneron is also developing monoclonal and bispecific antibodies with Sanofi, other collaborators, and independently, and has earlier-stage partnerships that bring new technology to the pipeline, including RNAi (Alnylam) and CRISPR-based gene editing (Intellia).
Financial Strength
10/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Cash-To-Debt | 3.63 | |||||
Equity-to-Asset | 0.78 | |||||
Debt-to-Equity | 0.1 | |||||
Debt-to-EBITDA | 0.53 | |||||
Interest Coverage | 60.69 | |||||
Piotroski F-Score | 3/9 | |||||
Altman Z-Score | 12.52 | |||||
Beneish M-Score | -2.29 | |||||
WACC vs ROIC |
Growth Rank
10/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | 16 | |||||
3-Year EBITDA Growth Rate | 5 | |||||
3-Year EPS without NRI Growth Rate | 7.9 | |||||
3-Year FCF Growth Rate | 22.8 | |||||
3-Year Book Growth Rate | 32.1 | |||||
Future 3-5Y EPS without NRI Growth Rate | 11.83 | |||||
Future 3-5Y Total Revenue Growth Rate | 7.89 |
Momentum Rank
1/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
5-Day RSI | 72.49 | |||||
9-Day RSI | 70.88 | |||||
14-Day RSI | 68.04 | |||||
6-1 Month Momentum % | 11.3 | |||||
12-1 Month Momentum % | 30.6 |
Liquidity Ratio
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Current Ratio | 5.44 | |||||
Quick Ratio | 4.62 | |||||
Cash Ratio | 2.8 | |||||
Days Inventory | 517.52 | |||||
Days Sales Outstanding | 147.81 | |||||
Days Payable | 114.28 |
Dividend & Buy Back
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -0.8 | |||||
Shareholder Yield % | 1.11 |
Profitability Rank
10/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Gross Margin % | 86.16 | |||||
Operating Margin % | 30.14 | |||||
Net Margin % | 32.04 | |||||
FCF Margin % | 23.57 | |||||
ROE % | 16.61 | |||||
ROA % | 12.99 | |||||
ROIC % | 18.87 | |||||
ROC (Joel Greenblatt) % | 50.19 | |||||
ROCE % | 15.6 | |||||
Years of Profitability over Past 10-Year | 10 |
GF Value Rank
1/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
PE Ratio | 31.86 | |||||
Forward PE Ratio | 25.73 | |||||
PE Ratio without NRI | 28.98 | |||||
Shiller PE Ratio | 40.32 | |||||
Price-to-Owner-Earnings | 52.74 | |||||
PEG Ratio | 1.64 | |||||
PS Ratio | 10.2 | |||||
PB Ratio | 4.7 | |||||
Price-to-Tangible-Book | 4.89 | |||||
Price-to-Free-Cash-Flow | 43.17 | |||||
Price-to-Operating-Cash-Flow | 33.78 | |||||
EV-to-EBIT | 26.87 | |||||
EV-to-Forward-EBIT | 24.18 | |||||
EV-to-EBITDA | 24.49 | |||||
EV-to-Forward-EBITDA | 22.74 | |||||
EV-to-Revenue | 9.27 | |||||
EV-to-Forward-Revenue | 8.87 | |||||
EV-to-FCF | 39.28 | |||||
Price-to-Projected-FCF | 1.96 | |||||
Price-to-DCF (Earnings Based) | 0.81 | |||||
Price-to-DCF (FCF Based) | 1.21 | |||||
Price-to-Median-PS-Value | 1.29 | |||||
Price-to-Peter-Lynch-Fair-Value | 1.85 | |||||
Price-to-Graham-Number | 2.51 | |||||
Price-to-Net-Current-Asset-Value | 11.84 | |||||
Price-to-Net-Cash | 68.74 | |||||
Earnings Yield (Greenblatt) % | 3.72 | |||||
FCF Yield % | 2.43 | |||||
Forward Rate of Return (Yacktman) % | 18.26 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Regeneron Pharmaceuticals Inc Executives
DetailsAnalyst Estimate
Key Statistics
Name | Value | ||
---|---|---|---|
Revenue (TTM) (Mil €) | 12,488.759 | ||
EPS (TTM) (€) | 34.971 | ||
Beta | -0.05 | ||
Volatility % | 21.55 | ||
14-Day RSI | 68.04 | ||
14-Day ATR (€) | 14.653949 | ||
20-Day SMA (€) | 1033.28 | ||
12-1 Month Momentum % | 30.6 | ||
52-Week Range (€) | 726 - 1090 | ||
Shares Outstanding (Mil) | 110.23 |
Piotroski F-Score Details
Year:
Component | Result | ||
---|---|---|---|
Piotroski F-Score | 3 | ||
Positive ROA | |||
Positive CFROA | |||
Higher ROA yoy | |||
CFROA > ROA | |||
Lower Leverage yoy | |||
Higher Current Ratio yoy | |||
Less Shares Outstanding yoy | |||
Higher Gross Margin yoy | |||
Higher Asset Turnover yoy |
Regeneron Pharmaceuticals Inc Filings
Filing Date | Document Date | Form | ||
---|---|---|---|---|
No Filing Data |
Regeneron Pharmaceuticals Inc Stock Events
Event | Date | Price(€) | ||
---|---|---|---|---|
No Event Data |
Regeneron Pharmaceuticals Inc Frequently Asked Questions
What is Regeneron Pharmaceuticals Inc(WBO:REGN)'s stock price today?
The current price of WBO:REGN is €1073.00. The 52 week high of WBO:REGN is €1090.00 and 52 week low is €726.00.
When is next earnings date of Regeneron Pharmaceuticals Inc(WBO:REGN)?
The next earnings date of Regeneron Pharmaceuticals Inc(WBO:REGN) is 2024-11-01 Est..
Does Regeneron Pharmaceuticals Inc(WBO:REGN) pay dividends? If so, how much?
Regeneron Pharmaceuticals Inc(WBO:REGN) does not pay dividend.
Press Release
Subject | Date | |||
---|---|---|---|---|
No Press Release |